Impact of HIV and Its Treatment on Reverse Cholesterol Transport

The Alfred

Status: Completed

Conditions: HIV Infections

Study type: Observational

Funder types: Other

Identifiers

NCT00168233

54/05

Details and patient eligibility

About

To investigate the effect of treatment of HIV infection with highly active antiretroviral therapy on individual steps of reverse cholesterol transport, endothelial function and intima-media thickness in HIV patients.

Enrollment: 44 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Male patients with HIV infection (3 groups of 50 patients each)
• HIV infected patients, naïve to ARV therapy and not likely to need to commence therapy for the duration of follow-up (12 months)
• HIV-infected patients, PI naïve, initiating therapy with PI-containing HAART (ARV naïve or NNRTI experienced changing to PI regimen)
• HIV-infected patients naïve to ARV therapy, initiating NNRTI-containing regimen

Exclusion criteria

• Treatment with any form of lipid lowering drugs, including fish oils.
• Body Mass Index greater than 27.

Trial design

44 participants in 3 patient groups

1

Description:

No antiretroviral therapy for 12 months

2

Description:

Initiating ARV therapy with an NNRTI based regimen

3

Description:

Initiating ARV therapy with a PI based regimen